Background. Interleukin 9 (IL-9) has been implicated in the pathogenesis of several tumor types, but the role of anti-IL-9 in pancreatic cancer remains unclear.
Introduction
Pancreatic cancer is one of the most aggressive metastatic malignancies, with a median survival rate of 6 months and a 5-year survival rate of 5%, and it ranks 4 th among cancer-related deaths in the USA. 1, 2 Surgery, chemotherapy and radiation therapy are the main treatment options for pancreatic cancer. However, the current treatment strategies are ineffective due to the fact that most of the patients are in advanced stages when they are first diagnosed. Therefore, finding novel therapeutic strategies is crucial to improve the effectiveness of treatment and to prolong the survival of pancreatic cancer patients.
Interleukin 9 (IL-9) is a multifunctional cytokine secreted by a host of pro-inflammatory immune cells, including Th2 cells, Th9 cells and Th17 cells. 3, 4 Interleukin 9 activates a heterodimeric receptor that comprises the IL-9 receptor α-chain (IL-9rα) and the γ-chain (IL-9rγ), and promotes the cross-phosphorylation of Janus kinase 1 (Jak1) and Janus kinase 3 (Jak3), which in turn induce the downstream activation of signal transducer and activator of transcription 3 (Stat3). 5 Interleukin 9 has contrasting roles depending on the type of cancer. Studies have reported that while IL-9 impaired tumor cell growth in B16 melanoma and CT26 colon adenocarcinoma-tumorbearing mice, 6 it could promote cancer growth and exhibit an anti-apoptotic function in various transformed cell lines. 7, 8 Thus, further research is needed in order to confirm the role of IL-9 in various cancers.
We have previously reported that IL-9 plays a tumorpromoting role in pancreatic cancer cell lines 9, 10 and therefore postulated that neutralizing IL-9 may exert a tumor-suppressing function in pancreatic cancer. In this study, we investigated the effect of the anti-IL-9 antibody on a subcutaneous Pan02 model and its potential mechanism. We report that anti-IL-9 antibody treatment can partly inhibit a pancreatic cancer tumor in vivo, which may provide an effective therapeutic strategy against pancreatic cancer. The study scheme is presented in Fig. 1 .
Material and methods

Cell culture
Murine pancreatic adenocarcinoma cell line Panc02 was obtained from the American Type Culture Collection (ATCC) and cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Waltham, USA) supplemented with 100 mg/mL of streptomycin, 100 U/mL of penicillin and 10% fetal bovine serum (Gibco). The culture medium was replaced every 48 h unless otherwise described and the cells were incubated in 5% CO 2 and 95% air at 37°C.
Pancreatic cancer syngeneic model
Forty-eight SPF-grade C57BL/6 mice (20-24 g), 5-6 weeks of age, were purchased from Hunan SJA Laboratory Animal Co. Ltd. (Changsha, China) and housed in the Animal Center of Guangxi Medical University, Nanning, China, under humidity-and temperature-controlled conditions with a 12-hour light/dark cycle. All procedures for handling the animals were approved by the Animal Experiments Ethics Committee of Guangxi Medical University. The cells were trypsinized and washed with phosphate-buffered saline (PBS) (consisting of potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, and potassium chloride) (Solarbio, Beijing, China). Panc02 cells (5 × 10 6 ) in 200 μL of PBS were subcutaneously injected into the right flank. Once the tumors reached about 50 mm 3 , the tumorbearing mice were tagged and divided into 3 groups (16 mice per group) and injected intravenously every 3 days for 18 days with sterile PBS, isotype control IgG (1 mg/kg) or anti-IL-9 antibody (1 mg/kg) (R&D Systems, Minneapolis, USA).
Tumor growth assessment
The tumor diameter was measured with a caliper every other day and the volume was calculated using the following formula:
(short diameter) 2 × (long diameter) × 0. 5. 11 Eight mice from each group were sacrificed on the 5 th day after the last treatment. Individual tumors from the mice were weighed and dissected for subsequent study. The inhibition rate was calculated using the following formula, in which A corresponds to the average tumor weight in the control group and B corresponds to tumor weight in the treated groups:
Survival observation
Surrogate endpoints for survival were used: either when the tumors reached an average diameter of 20 mm or when they became ulcerated. 12, 13 The survival time of the remaining mice (8 mice per group) was recorded at the end 
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anti-IL9 injection C57BL/6 mice of the observation period. The prolonged rate of survival time was calculated using the following formula, in which A corresponds to the average tumor weight in the control group and B corresponds to the average tumor weight in the treated groups:
During treatment with anti-IL-9 antibody, we also observed whether the mice displayed abnormal behavior, such as an altered mental state or weight loss.
RNA isolation and qRT-PCR
The total RNA was extracted from tumor tissues using an RNAiso plus Kit (TaKaRa, Beijing, China). cDNA synthesis was performed using a PrimeScript TM RT reagent Kit (TaKaRa). Real-time polymerase chain reaction (RT-PCR) was performed with PrimeScript TM RT PCR Master Mix according to the manufacturer's protocol. The forward and reverse primers used for PCR were as follows: IL-9 forward 5'-ATG TTG GTG ACA TAC ATC CTT GC-3' and reverse 5'-TGA CGG TGG ATC ATC CTT CAG-3'; IL-9r forward 5'-GTA TTT ACA GGA TCG ACT GCC AC-3' and reverse 5'-CCC AGA AGG TGC ATT TGT GTT-3'; Jak1 forward 5'-GGA GTA CTA CAC AGT CAA GGA CGA-3' and reverse 5'-AAA CAT TCC GGA GCG TAC C-3'; Jak3 forward 5'-CCA GAC CAG CAG AGG GAC TT-3' and reverse 5'-CCA AAG CGA ACA GCA GTA GGC-3'; Stat3 forward 5'-GTT CCT GGC ACC TTG GAT T-3' and reverse 5'-CAA CGT GGC ATG TGA CTC TT-3'.
The relative expression was normalized to GAPDH and gene expression was analyzed using the 2−ΔΔCT method.
Immunohistochemical analysis
The tumor tissues were formalin-fixed and paraffinembedded, and specimen sections 4 μm in thickness were prepared. The slides were treated in an autoclave oven for 5-10 min to unmask the heat-induced antigen and they were blocked with 5% goat serum in PBS for 1 h. The sections were incubated with primary antibodies against STAT3 (Cat# ab68153, 1:500, Abcam, Cambridge, UK), pSTAT3 (Cat# ab76315, 1:1000, Abcam), matrix metalloproteinases (MMPs) 2 and 9 (Cat# BM4098 and BM4075, 1:500, Boster Biological Technology, Pleasanton, USA), and vascular endothelial growth factor A (VEGF A) (Cat# M00045, 1:400, Boster Biological Technology) at 4°C overnight, followed by the secondary antibody (Cat# A-21074, Zymed, Waltham, USA) at room temperature for 30 min. Diaminobenzidine (DAB) was used to facilitate the locating of the antibody. Finally, the slides were rinsed in PBS and then counterstained with hematoxylin. The stained sections were captured using an Olympus DP72 microscope (Olympus Corporation, Shinjuku, Tokyo, Japan). The positively-labeled cells and negative cells in 5 randomly selected fields were counted at ×200 magnification by 2 independent observers and the mean percentage of positive cells was calculated using Image-Pro Plus v. 6.0 (Media Cybernetics, Rockville, USA).
Western blot analysis
The proteins were collected from tumor tissues using RIPA lysis buffer (consisting of sodium chloride, tris(hydroxymethyl)aminomethane, sodium deoxycholate, and NP-40 lysis buffer) containing protease inhibitors and phosphatase inhibitors (Roche, Basel, Switzerland). The lysates were subjected to centrifugation at 12,000 rpm for 20 min at 4°C. The total protein was then measured with Pierce BCA assay (Solarbio). One part of 5× sample buffer and 4 parts of equal concentrations of protein were mixed and heated at 95°C for 10 min. Equal amounts of lysates were separated with 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 90 min and were blotted onto a polyvinylidene fluoride (PVDF) membrane (Merck Millipore, Burlington, USA). The membranes were blocked with 1× TBS containing 0.1% Tween 20 and 2% BSA at room temperature for 1 h and subsequently incubated with rabbit monoclonal anti-STAT3 (phospho-Y705; 1:2,000; Abcam) at 4°C overnight, followed by secondary fluorescent antibodies labeled with LI-COR IRDye 680 (LI-COR Biosciences, Lincoln, USA) at room temperature for 1 h. The signals were determined using Odyssey Infrared Imaging System and quantitated with LICOR imaging software (LI-COR Biosciences).
ELISA for IL-9
The tumor tissues were washed and homogenized in cold PBS before being stored at −20°C overnight. The tumor homogenates had undergone 2 freeze-thaw cycles and were subsequently centrifuged at 5,000 g for 5 min at 4°C. Interleukin 9 levels in the supernatant were determined using enzyme-linked immunosorbent assay (ELISA) Kits according to the manufacturer's instructions (Cusabio, Wuhan, China). The optical density was measured at 450 nm with a standard curve range of 15.6 pg/mL to 1,000 pg/mL.
Statistical analysis
The data is expressed as mean values ± standard deviation (SD). All data was analyzed with SPSS v. 17.0 software (SPSS Inc., Chicago, USA). Comparisons between 2 groups were carried out using Student's t-test while comparisons among multiple groups were analyzed using the one-way analysis of variance (ANOVA) method followed by the least significant differences (LSD) post hoc test. The χ 2 test and Fisher's exact probability test were used to compare enumeration data. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. Differences in means were considered statistically significant when p < 0.05.
Results
Blockading IL-9 slows in vivo pancreatic tumor growth
The tumors in the anti-IL-9 group showed significantly slower growth rates than those in the PBS and IgG groups (p < 0.05; Fig. 2A ). Significant differences in tumor volume among the 3 groups were observed on day 17, whereas no significant differences between the PBS group and the IgG group were found. Additionally, tumor weight was significantly lower in the anti-IL-9 group than in both the PBS and IgG groups (p < 0.05; Fig. 2B ). At the end of the experiment, the anti-IL-9 group achieved 24.2% tumor growth inhibition (p < 0.05 vs the control group). These results suggest that the anti-IL-9 antibody can inhibit tumor growth.
Neutralizing IL-9 extended survival time in a murine model
Measuring the time from Panc02 cell injection until the surrogate endpoint for survival, we found that administering anti-IL-9 significantly prolonged the survival of tumor-bearing mice compared to the PBS-or IgG-administered groups (p < 0.05; Fig. 3 ): the increase in survival time among the anti-IL-9 group was 16.8%. Additionally, exposure to anti-IL-9 treatment did not lead to abnormal behavior or dramatic changes in the body weight of these animals, implying its tolerability during a sustained period of administration.
Administering anti-IL-9 antibody decreased IL-9 concentration in tumor tissue
To determine whether the anti-IL-9 antibody treatment blocked IL-9 activity, the concentration of IL-9 in the tumor tissue was detected with ELISA. We observed a significant reduction in IL-9 activity in the anti-IL-9-treated mice compared to the PBS-treated and IgGtreated mice (p < 0.05; Fig. 4A ). Similarly, quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis suggests that the expression of IL-9 mRNA was significantly lower after anti-IL-9 treatment (p < 0.05; Fig. 4B ).
Treating with anti-IL-9 antibody alters the JAK-STAT pathway in tumor-bearing mice
Because IL-9-mediated signal transduction activated molecular members of the STAT3, 5 MAPK and PI3K pathways 14 -which were potentially involved in the activity of the IL-9-IL-9R axis -we postulated that the blockade of IL-9 may mediate the JAK/STAT pathway in pancreatic-tumor-bearing mice. As is shown in Fig. 5 , the relative expression of Jak1 and Jak3 mRNA Fig. 2 . Anti-IL-9 treatment results in slowed tumor growth in vivo. When tumors reached approx. 50 mm 3 , mice were randomly separated into 3 cohorts: PBS group, IgG group and anti-IL-9 group, and tumor growth was monitored. A -mice treated with anti-IL-9 antibody showed significant delay in tumor growth as compared to control groups (p < 0.05). Each data point represents average tumor volume (n = 8/each) and error bars denote standard error; B -comparison of weight of tumor in different groups (n = 8/each) *p < 0.05 compared with PBS or IgG control group; data is shown as mean ±SD. in the anti-IL-9 group was markedly lower than that of the PBS or IgG groups (p < 0.05; Fig. 5B,C) , whereas the mRNA levels of IL-9r and Stat3 did not show any difference across all 3 groups (p > 0.05; Fig. 5A,D) . Similarly, the western blot results showed that IL-9 inhibition failed to suppress STAT3 expression in the anti-IL-9 group (p > 0.05; Fig. 6A,B ), but pSTAT3 expression was effectively decreased in the tumor tissues from the anti-IL-9 group compared to those treated with PBS or IgG antibody (p < 0.05; Fig. 6A,C) . Consistent with the above results, the immunohistochemistry results revealed that tumor tissues in the anti-IL-9 group expressed significantly less pSTAT3 protein when compared to the other groups (p < 0.05; Fig. 7) . 
Treating with anti-IL-9 antibody decreases STAT3-regulated downstream target products
Next, we determined whether suppressing pSTAT3 with the anti-IL-9 antibody could initiate the suppression of STAT3-regulated genes, MMP 2 and 9 and VEGF. 15 As shown in Fig. 7 , the tumor cells and stroma showed strong reactivity to the antibodies for STAT3, pSTAT3, MMP 2 and 9, and VEGF. Our immunohistochemistry results showed a significant reduction in pSTAT3-, MMP2-and MMP9-positive cells (p < 0.05; Fig. 7) , whereas the number of STAT3-and VEGF-positive cells was not significantly different in the anti-IL-9 group compared to the PBS and IgG groups (p > 0.05; Fig. 7 ). We concluded that anti-IL-9 antibody may inhibit pancreatic cancer growth by downregulating JAK/STAT3 signaling.
Discussion
Immune cells and the cytokines secreted by them are involved in a multitude of physiological and pathological processes. 16, 17 Interleukin 9, a pleiotropic cytokine secreted by a number of immune cells, is implicated in the pathogenesis of several diseases and conditions. 5,6 Interleukin 9 facilitates an immunosuppressive environment to promote tumor growth or to restrain tumor progression based on tumor type. 18 Interleukin 9 was shown to inhibit the growth of HTB-72 melanoma cells and it favors the survival of CD4 + CD8 + double-positive T cells; it also displays cytotoxic activity against melanoma cells. 19 However, IL-9 also substantially contributes to the proliferation and migration of lung cancer cells while helping them escape apoptosis. 20 Similar biological functions of IL-9 were also observed in breast cancer, 18 colon carcinoma 18 and hematopoietic malignancies, such as diffuse large B-cell lymphoma (DLBCL). 8 Moreover, IL-9 can protect DLBCL cell lines LY1 and LY8 from prednisolone and rituximab, whereas the effect of IL-9 on DLBCL cell lines could be impaired and reversed through the knock-down of IL-9R. 8 Because IL-9 is strongly associated with tumor progression, blocking IL-9 may be an applicable strategy for tumor treatment. Smith et al. showed that the neutralization of IL-9 in conjunction with CpG-ODN injection could induce tumor rejection in BALB-neuT-and MUC-1-tolerant tumor models. 21 Anti-IL-9 treatment inhibited tumor growth in WT mice with breast cancer cell line 4T1. 18 In this setting, we investigated whether targeting IL-9 could influence pancreatic cancer progression. A murine Panc02 model is widely used in pre-clinical study, and immunocompetent C57BL/6 mice provide a tumor microenvironment similar to a real immune environment. 22, 23 A significantly slower tumor growth rate and lower tumor weight were observed in the anti-IL-9 group compared to the PBS or IgG groups, indicating that the anti-IL-9 antibody could limit the growth of pancreatic cancer.
Next, we investigated the effect of anti-IL-9 treatment on survival. The results showed that neutralizing IL-9 significantly prolonged the survival time in Panc02-tumorbearing mice. Notably, we observed that tumor growth occurred constantly in the survival period after the last administration of anti-IL-9, suggesting that the anti-IL-9 antibody could inhibit tumor growth only in a period of constitutive anti-IL-9 antibody injection, but failed to provide a long-term solution to inhibit tumor growth completely. In addition, the concentration of IL-9 in tumor tissue from the anti-IL-9 group was markedly reduced. Taken together, our results suggest that neutralizing IL-9 could inhibit the growth of pancreatic cancer in vivo by inhibiting IL-9.
The STAT3 signaling is involved in the regulation of the cell cycle, apoptosis, angiogenesis, metastasis, and immune evasion across a variety of tumor types, including pancreatic cancer. [24] [25] [26] Notably, sustained activation of STAT3 at phosphorylated Tyr705 exists in 30-100% of human tumor specimens and in several pancreatic cancer cell lines. 27 Moreover, STAT3 was previously reported to be potentially involved in the IL-9-IL-9R axis, and IL-9-induced receptor activation promotes phosphorylation of JAK1 and JAK3, which leads to the downstream activation of the STAT3 pathway. 5, 14, 28 Dysregulation of IL-9 in vitro could lead to autonomous cell growth and malignant transformation of lymphoid cells, which was strongly related to constitutive activation of the JAK/STAT pathway. 29 Thus, we postulate that an IL-9 blockade may affect the STAT3 pathway. Consistent with this hypothesis, our results showed a dramatic reduction of JAK1, JAK3 and pSTAT3 in the tumor tissue from the mice injected with the anti-IL-9 antibody, so we concluded that the STAT3 pathway may be implicated in this process.
The activation of STAT3 has been reported to induce MMP9 expression 30 and to upregulate VEGF by directly binding to the VEGF promoter, 31 thereby facilitating cell invasion. In this study, we further examined whether the alteration of STAT3 could influence the expression of MMP9 and VEGF. We observed that the expression of MMP2 and MMP9 was reduced after the administration of the anti-IL-9 antibody, but no significant change in the expression of VEGF was observed among the 3 groups, implying that the inhibition of the STAT3 pathway caused by anti-IL-9 could further suppress the expression of MMP2 and MMP9, but had no effect on VEGF expression.
Although our study elucidated the effect of anti-IL-9 in pancreatic cancer and its possible underlying mechanism, there were several limitations to this study. The pancreatic cancer mouse model was established using Panc02 cells; the effect and mechanism of IL-9 on pancreatic cancer should be verified in a mouse model established by the use of other pancreatic cancer cells. Although we showed an anti-IL-9-mediated STAT3 pathway inhibition in pancreatic cancer, a rescue experiment using STAT3 pathway inhibitors is needed to verify whether the pathway is truly involved in this process.
Conclusions
Our study demonstrated that treating pancreatic-tumorbearing mice with the anti-IL-9 antibody can delay tumor growth, possibly via the inhibition of the STAT3 signaling pathway. Further experimentation using other pancreatic cancer mouse models is required to validate these results.
